Unique ID issued by UMIN | UMIN000035522 |
---|---|
Receipt number | R000040469 |
Scientific Title | Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis |
Date of disclosure of the study information | 2019/01/11 |
Last modified on | 2021/07/19 14:30:59 |
Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis
Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis
Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis
Effect of placenta supplement on chronic fatigue in the patient with moderately advanced liver cirrhosis
Japan |
liver cirrhosis
Hepato-biliary-pancreatic medicine |
Others
NO
To examine the effect to the fatigue of the placenta supplement on cirrhosis patient
Efficacy
Confirmatory
Estimation of general fatigue by questionnaire before, 12, 24 weeks after beginning administration of placenta extract and 12 weeks after end of administration
Estimation of liver disease specialized QOL questionnaire, total bilirubin, total protein, serum albumin annmonia, ferritin, prothrombin time, AST, ALT, BUN, serum creatinine, free fatty acid, IRI, blood suger, Na, K, Cl, hyaluronic acid, type IV collagen 7s, M2BPGi, hepcidin, BMP receptor binging factor, check sheet for muscle cramp (visual analogue scale), total body water, total body muscle volume, total body fat volume estimated body composition analyzer and grip before, 12, 24 weeks after beginning administration of placenta extract and 12 weeks after end of administration
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
NO
1
Treatment
Food |
Placenta extract ( JBP porcine 100: 350mg a capsule), 6 capsules per day, 24 weeks
20 | years-old | <= |
90 | years-old | > |
Male and Female
1) Patients over the age of twenty with Child grade B liver cirrhosis
2) Consent is obtained in writing
1)patients hypersensitive to placenta
2)patients with uncontrolled hepatoma
3) complicated other malignancy and survival prognosis is one year or less
4) psychosomatic disorder or neurological disorder except for hepatic encephalopathy
5) severe infection example for tuberculosis
10
1st name | Hiroshi |
Middle name | |
Last name | Tobita |
Shimane University Hospital
Hepatology
693-8501
89-1, Enya-cho, Izumo-shi, Shimane
0853-20-2190
ht1020@med.shimane-u.ac.jp
1st name | Hiroshi |
Middle name | |
Last name | Tobita |
Shimane University Hospital
Hepatology
693-8501
89-1, Enya-cho, Izumo-shi, Shimane
0853-20-2190
ht1020@med.shimane-u.ac.jp
Shimane University Hospital
Shimane University Hospital
Other
Shimane University Hospital
Enya-cho, 89-1
0853202190
kenkyu@med.shimane-u.ac.jp
NO
2019 | Year | 01 | Month | 11 | Day |
Unpublished
Terminated
2019 | Year | 01 | Month | 10 | Day |
2017 | Year | 04 | Month | 24 | Day |
2019 | Year | 03 | Month | 24 | Day |
2020 | Year | 12 | Month | 31 | Day |
2019 | Year | 01 | Month | 11 | Day |
2021 | Year | 07 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040469